<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130986</url>
  </required_header>
  <id_info>
    <org_study_id>1R01GM101197</org_study_id>
    <secondary_id>1R01GM101197</secondary_id>
    <nct_id>NCT02130986</nct_id>
  </id_info>
  <brief_title>Procalcitonin Antibiotic Consensus Trial (ProACT)</brief_title>
  <acronym>ProACT</acronym>
  <official_title>Procalcitonin Antibiotic Consensus Trial (ProACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ProACT study is a 5 year, multicenter study that will test the effect of implementation
      of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency
      Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a need for improved decision-making for antibiotic prescription in acute suspected
      infection. Infections, particularly in the early stages, can have protean manifestations,
      often do not manifest with &quot;classic&quot; signs, and clinically overlap with non-infectious
      conditions. However, the imperative to quickly give antibiotics for bacterial infection has
      led to antibiotic overuse and resistance.

      Strategies that combine novel diagnostics with therapeutics have improved decision-making in
      oncology, cardiology, and other fields. These strategies aim to identify those patients most
      likely to be helped or harmed by the therapeutic intervention and allow more individualized
      care. This approach takes diagnostics to the next level, by demanding a test not only measure
      well, but also that clinical care be improved by tying the test to a treatment strategy.

      Procalcitonin, a novel biomarker of bacterial infection, may help physicians make more
      appropriate antibiotic decisions. Lower respiratory tract infection (LRTI) is an ideal trial
      population. LRTI accounts for a large proportion of antibiotic prescription, and exemplifies
      the imprecise clinical phenotype of infection.However, key questions of generalizability and
      safety preclude widespread application.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2014</start_date>
  <completion_date type="Actual">July 21, 2017</completion_date>
  <primary_completion_date type="Actual">July 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Antibiotic Exposure Days</measure>
    <time_frame>30 days</time_frame>
    <description>Total antibiotic exposure, defined as the total number of antibiotic-days by Day 30.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Outcome</measure>
    <time_frame>30 days</time_frame>
    <description>Primary Safety Outcome - Combined endpoint of adverse outcomes (death, endotracheal intubation, vasopressors, renal failure, lung abscess/empyema, pneumonia in non-CAP patient, and hospital readmissions) that could be attributable to withholding antibiotics in lower respiratory tract infection (LRTI).
Number is based on the number of participants that experienced any adverse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Prescription in Emergency Department(ED)</measure>
    <time_frame>While in the ED or before ED discharge (majority patients &lt; 1 day)</time_frame>
    <description>Antibiotic prescription in the ED includes post-randomization receipt of antibiotics in ED and provision of an antibiotic prescription for patients at the time of discharge from the ED.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1664</enrollment>
  <condition>Lower Respiratory Tract Infection (LRTI)</condition>
  <arm_group>
    <arm_group_label>Procalcitonin (PCT) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telephone Visit at Day 15 and Day 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procalcitonin level</intervention_name>
    <description>A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.</description>
    <arm_group_label>Procalcitonin (PCT) group</arm_group_label>
    <other_name>PCT level</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Results of procalcitonin (PCT) level to treating clinician</intervention_name>
    <description>In the ED, we will quickly (&lt;1 hour goal) provide clinicians the procalcitonin result.</description>
    <arm_group_label>Procalcitonin (PCT) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Provide procalcitonin guideline to treating clinician</intervention_name>
    <description>Procalcitonin antibiotic guideline --
Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation
&lt; 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)
0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)
&gt; 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)
&gt; 0.5 -- Very likely -- Antibiotics strongly recommended(2)
Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.
For outpatients, antibiotic duration based on level (&gt; 0.25-0.5 ug/L:3 days; &gt; 0.5-1.0 ug/L:5 days; &gt;1.0 ug/L:7 days). Physician follow-up is recommended.</description>
    <arm_group_label>Procalcitonin (PCT) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone Visit</intervention_name>
    <description>We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
    <arm_group_label>Procalcitonin (PCT) group</arm_group_label>
    <arm_group_label>Usual Care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  A primary clinical diagnosis in the ED of acute LRTI (&lt; 28 days duration)

          -  Clinician willing to consider procalcitonin in antibiotic decision-making

        Exclusion Criteria:

          -  Systemic antibiotics before ED presentation (All prophylactic antibiotic regimens, OR
             received &gt;1 dose within 72 hours prior to ED presentation)

          -  Current vasopressor use

          -  Mechanical ventilation (via endotracheal tube)

          -  Known severe immunosuppression

          -  Accompanying non-respiratory infections

          -  Known lung abscess or empyema

          -  Chronic dialysis

          -  Metastatic cancer

          -  Surgery in the past 7 days (excluding minor surgery such as skin biopsy)

          -  Incarcerated or homeless

          -  Enrolled in ProACT in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T Huang, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Institute of Rural Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University, College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey College of Medicine; Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meisner M. Biomarkers of sepsis: clinically useful? Curr Opin Crit Care. 2005 Oct;11(5):473-80. Review.</citation>
    <PMID>16175035</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly. 2009 Jun 13;139(23-24):318-26. doi: smw-12584. Review.</citation>
    <PMID>19529989</PMID>
  </reference>
  <reference>
    <citation>Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 Jan;86(1):396-404.</citation>
    <PMID>11232031</PMID>
  </reference>
  <reference>
    <citation>Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003 Mar 15;36(6):823-4; author reply 826-7.</citation>
    <PMID>12627371</PMID>
  </reference>
  <reference>
    <citation>Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003. Review.</citation>
    <PMID>16715031</PMID>
  </reference>
  <reference>
    <citation>Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med. 2007 Jul;50(1):34-41. Epub 2006 Dec 11. Review.</citation>
    <PMID>17161501</PMID>
  </reference>
  <reference>
    <citation>Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39(2):206-17. Epub 2004 Jul 2. Review. Erratum in: Clin Infect Dis. 2005 May 1;40(9):1386-8.</citation>
    <PMID>15307030</PMID>
  </reference>
  <reference>
    <citation>Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Müller B, Tamm M. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006 Jul 8;136(27-28):434-40.</citation>
    <PMID>16862463</PMID>
  </reference>
  <reference>
    <citation>Hirakata Y, Yanagihara K, Kurihara S, Izumikawa K, Seki M, Miyazaki Y, Kohno S. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008 Jun;61(2):170-4. doi: 10.1016/j.diagmicrobio.2008.01.014. Epub 2008 Mar 7.</citation>
    <PMID>18329217</PMID>
  </reference>
  <reference>
    <citation>Prieto B, Llorente E, González-Pinto I, Alvarez FV. Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications. Clin Chem Lab Med. 2008;46(5):660-6.</citation>
    <PMID>18839468</PMID>
  </reference>
  <reference>
    <citation>Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008 Sep;49(9):1752-61. doi: 10.1080/10428190802258956.</citation>
    <PMID>18661397</PMID>
  </reference>
  <reference>
    <citation>Charles PE, Kus E, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis. 2009 Apr 22;9:49. doi: 10.1186/1471-2334-9-49.</citation>
    <PMID>19386110</PMID>
  </reference>
  <reference>
    <citation>Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, Angus DC; GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008 Jul;52(1):48-58.e2. doi: 10.1016/j.annemergmed.2008.01.003. Epub 2008 Mar 17.</citation>
    <PMID>18342993</PMID>
  </reference>
  <reference>
    <citation>Müller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, Nusbaumer C, Tamm M, Christ-Crain M. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007 Mar 2;7:10.</citation>
    <PMID>17335562</PMID>
  </reference>
  <reference>
    <citation>Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M, Kouatchet A, Mourvillier B, Dellamonica J, Picard W, Schmidt M, Boulain T, Brun-Buisson C; A/H1N1 REVA-SRLF Study Group. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 2011 May;37(5):796-800. doi: 10.1007/s00134-011-2189-1. Epub 2011 Mar 3.</citation>
    <PMID>21369807</PMID>
  </reference>
  <reference>
    <citation>Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011 Apr;(169):1-38.</citation>
    <PMID>21614897</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7.</citation>
    <PMID>14987884</PMID>
  </reference>
  <reference>
    <citation>Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007 Jan;131(1):9-19.</citation>
    <PMID>17218551</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009 Sep 9;302(10):1059-66. doi: 10.1001/jama.2009.1297.</citation>
    <PMID>19738090</PMID>
  </reference>
  <reference>
    <citation>Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology. 2011 Jul;16(5):819-24. doi: 10.1111/j.1440-1843.2011.01978.x.</citation>
    <PMID>21507143</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <results_first_submitted>December 2, 2018</results_first_submitted>
  <results_first_submitted_qc>January 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>David T. Huang, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor of Critcal Care and Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>procalcitonin (PCT)</keyword>
  <keyword>lower respiratory tract infection (LRTI)</keyword>
  <keyword>antibiotic exposure</keyword>
  <keyword>antibiotic decision making</keyword>
  <keyword>community acquired pneumonia (CAP)</keyword>
  <keyword>chronic obstructive pulmonary disease (COPD) exacerbation</keyword>
  <keyword>acute asthma exacerbation</keyword>
  <keyword>acute bronchitis</keyword>
  <keyword>procalcitonin guideline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02130986/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02130986/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in the Emergency Department (ED) if they had a primary clinical diagnosis of acute Lower Respiratory Tract Infection [LRTI] (&lt; 28 days duration) and their key clinician was willing to consider Procalcitonin (PCT) result in Antibiotic (ABX) decision making.</recruitment_details>
      <pre_assignment_details>Only 8 patients (4 in each arm) were entirely excluded because they withdrew all consent to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Procalcitonin (PCT) Group</title>
          <description>Procalcitonin (PCT)
Results of procalcitonin level provided to treating clinician (initial in the ED, 6-24 hrs after initial. and Day 3, 5, 7 if in hospital AND on abx or at the treating clinician's discretion)
Telephone Visit at Day 15 and Day 30 to collect ABX days, post-d/c resource use and AQ-20 questionnaire
Bio-bank samples collected in ED for storage at Coordinating Center</description>
        </group>
        <group group_id="P2">
          <title>Usual Care (UC) Group</title>
          <description>Usual Care
Telephone Visit at Day 15 and Day 30 to collect ABX days, post-d/c resource use and AQ-20 questionnaire
Bio-bank samples collected in ED for storage at Coordinating Center</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="830"/>
                <participants group_id="P2" count="834"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
                <participants group_id="P2" count="670"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only excluded 4 patients in each group for a total of 8 subjects. These 8 subjects withdrew all consent for participation.</population>
      <group_list>
        <group group_id="B1">
          <title>Procalcitonin (PCT) Group</title>
          <description>Procalcitonin level: A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
Results of procalcitonin (PCT) level to treating clinician: In the ED, we will quickly (&lt;1 hour goal) provide clinicians the procalcitonin result.
Provide PCT guideline to treating clinician: Procalcitonin antibiotic guideline --
PCT level (ug/L)-- Bacterial etiology -- Recommendation &lt; 0.1-- Very unlikely -- Antibiotics strongly discouraged 0.1 - 0.25 -- Unlikely--Antibiotics discouraged &gt; 0.25 - 0.5--Likely -- Antibiotics recommended &gt; 0.5-- Very likely -- Antibiotics strongly recommended
Telephone Visit: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
        </group>
        <group group_id="B2">
          <title>Usual Care (UC) Group</title>
          <description>Telephone Visit at Day 15 and Day 30
Telephone Visit: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="826"/>
            <count group_id="B2" value="830"/>
            <count group_id="B3" value="1656"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="603"/>
                    <measurement group_id="B2" value="596"/>
                    <measurement group_id="B3" value="1199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="18.4"/>
                    <measurement group_id="B2" value="53.2" spread="18.7"/>
                    <measurement group_id="B3" value="53.1" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="469"/>
                    <measurement group_id="B2" value="476"/>
                    <measurement group_id="B3" value="945"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="354"/>
                    <measurement group_id="B3" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                    <measurement group_id="B2" value="470"/>
                    <measurement group_id="B3" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity was self-reported and information was requested prior to race description</description>
          <population>Race and ethnic group were reported by the patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="815"/>
                    <count group_id="B2" value="812"/>
                    <count group_id="B3" value="1627"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="826"/>
                    <count group_id="B2" value="830"/>
                    <count group_id="B3" value="1656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="826"/>
                    <measurement group_id="B2" value="830"/>
                    <measurement group_id="B3" value="1656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Antibiotic Exposure Days</title>
        <description>Total antibiotic exposure, defined as the total number of antibiotic-days by Day 30.</description>
        <time_frame>30 days</time_frame>
        <population>Mixed modeling was used to impute missing data for the intention-to-treat analysis for the primary outcome since not all patients could be reached for the 30 day interview (which collected 30 day antibiotic use).</population>
        <group_list>
          <group group_id="O1">
            <title>Procalcitonin (PCT) Group</title>
            <description>Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
Procalcitonin level: A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
Results of procalcitonin (PCT) level to treating clinician: In the ED, we will quickly (&lt;1 hour goal) provide clinicians the procalcitonin result.
Provide procalcitonin guideline to treating clinician.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Group</title>
            <description>Telephone Visit at Day 15 and Day 30
Telephone Visit: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
          </group>
        </group_list>
        <measure>
          <title>Total Antibiotic Exposure Days</title>
          <description>Total antibiotic exposure, defined as the total number of antibiotic-days by Day 30.</description>
          <population>Mixed modeling was used to impute missing data for the intention-to-treat analysis for the primary outcome since not all patients could be reached for the 30 day interview (which collected 30 day antibiotic use).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="5.8"/>
                    <measurement group_id="O2" value="4.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Outcome</title>
        <description>Primary Safety Outcome - Combined endpoint of adverse outcomes (death, endotracheal intubation, vasopressors, renal failure, lung abscess/empyema, pneumonia in non-CAP patient, and hospital readmissions) that could be attributable to withholding antibiotics in lower respiratory tract infection (LRTI).
Number is based on the number of participants that experienced any adverse outcome.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Procalcitonin (PCT) Group</title>
            <description>Provide PCT results and procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30 for # of ABX days
A procalcitonin (PCT) will be drawn within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion. Results &amp; guideline provided to the treating clinician.
PCT guideline to treating clinician:
Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation
&lt; 0.1 --Very unlikely -- Antibiotics strongly discouraged
0.1 - 0.25 -- Unlikely --Antibiotics discouraged
&gt; 0.25 -- 0.5--Likely--Antibiotics recommended
&gt; 0.5 --Very likely -- Antibiotics strongly recommended</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Group</title>
            <description>Telephone Visit at Day 15 and Day 30
Telephone Visit: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Outcome</title>
          <description>Primary Safety Outcome - Combined endpoint of adverse outcomes (death, endotracheal intubation, vasopressors, renal failure, lung abscess/empyema, pneumonia in non-CAP patient, and hospital readmissions) that could be attributable to withholding antibiotics in lower respiratory tract infection (LRTI).
Number is based on the number of participants that experienced any adverse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Procalcitonin algorithm implementation increases or does not change the proportion of subjects who experience a composite endpoint of adverse outcomes by Day 30. The prespecified noninferiority margin is 4.5 percentage.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.015</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibiotic Prescription in Emergency Department(ED)</title>
        <description>Antibiotic prescription in the ED includes post-randomization receipt of antibiotics in ED and provision of an antibiotic prescription for patients at the time of discharge from the ED.</description>
        <time_frame>While in the ED or before ED discharge (majority patients &lt; 1 day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Procalcitonin (PCT) Group</title>
            <description>Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
Procalcitonin level: A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
Results of procalcitonin (PCT) level to treating clinician: In the ED, we will quickly (&lt;1 hour goal) provide clinicians the procalcitonin result.
Provide procalcitonin guideline to treating clinician: Procalcitonin antibiotic guideline --
Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation &lt; 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1) 0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Group</title>
            <description>Telephone Visit at Day 15 and Day 30
Telephone Visit: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30</description>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Prescription in Emergency Department(ED)</title>
          <description>Antibiotic prescription in the ED includes post-randomization receipt of antibiotics in ED and provision of an antibiotic prescription for patients at the time of discharge from the ED.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="826"/>
                <count group_id="O2" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>By day 30.</time_frame>
      <desc>All events were reviewed and assessed by the Principal Investigator at the participating site.
8 patients (4 in each arm) were entirely excluded because they withdrew all consent to participate.
Most specific terms are reported in the Adverse Event Section.</desc>
      <group_list>
        <group group_id="E1">
          <title>Procalcitonin (PCT) Group</title>
          <description>Procalcitonin (PCT)
Results of procalcitonin level provided to treating clinician (initial in the ED, 6-24 hrs after initial. and Day 3, 5, 7 if in hospital AND on abx or at the treating clinician's discretion)
Telephone Visit at Day 15 and Day 30 to collect ABX days, post-d/c resource use and AQ-20 questionnaire
Bio-bank samples collected in ED for storage at Coordinating Center</description>
        </group>
        <group group_id="E2">
          <title>Usual Care Group</title>
          <description>Usual Care
Telephone Visit at Day 15 and Day 30 to collect ABX days, post-d/c resource use and AQ-20 questionnaire
Bio-bank samples collected in ED for storage at Coordinating Center</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE Version 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="826"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="826"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Patient developed pseudomonas PNA while in hospital</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE Version 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="826"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraoperative musculoskeletal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>No descriptions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Bronchial stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="826"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="830"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="826"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="830"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David T Huang, MD, MPH, Associate Professor</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-647-6818</phone>
      <email>huangdt@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

